Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia

被引：20

作者：

Ruggiu, Mathilde ^{[1
]}

Oberkampf, Florence ^{[1
]}

Ghez, David ^{[2
]}

Cony-Makhoul, Pascale ^{[3
]}

Beckeriche, Florence ^{[4
]}

Cano, Isabelle ^{[1
]}

Taksin, Anne L. ^{[1
]}

Benbrahim, Omar ^{[5
]}

Ghez, Stephanie ^{[1
]}

Farhat, Hassan ^{[1
]}

Rigaudeau, Sophie ^{[1
]}

de Gunzburg, Noemie ^{[1
]}

Lara, Diane ^{[1
]}

Terre, Christine ^{[6
]}

Raggueneau, Victoria ^{[6
]}

Garcia, Isabel ^{[6
]}

Spentchian, Marc ^{[6
]}

De Botton, Stephane ^{[2
]}

Rousselot, Philippe ^{[1
,7
]}

机构：

[1] Ctr Hosp Versailles, Dept Hematol, Versailles, France

[2] Inst Gustave Roussy, Dept Hematol, Villejuif, France

[3] Ctr Hosp Annecy Genevois, Dept Hematol, Pringy, France

[4] Hop Henri Mondor, APHP, Hematol Dept, Creteil, France

[5] Hop La Source, Dept Hematol, Orleans, France

[6] Ctr Hosp Versailles, Hematol Lab, Versailles, France

[7] Univ Versailles St Quentin En Yvelines, UMR1173, Paris, France

来源：

LEUKEMIA & LYMPHOMA | 2018年 / 59卷 / 07期

关键词：

Advanced phase CML; azacytidine; tyrosine kinase inhibitors; CHRONIC MYELOID-LEUKEMIA; BLAST CRISIS; IMATINIB-RESISTANT; LYMPHOCYTIC-LEUKEMIA; DNA METHYLATION; CPG ISLANDS; FOLLOW-UP; THERAPY; DASATINIB; EFFICACY;

D O I：

10.1080/10428194.2017.1397666

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Although the tyrosine kinase inhibitor (TKI) era has brought great improvement in outcome in chronic myelogenous leukemia (CML), prognosis of accelerated phase or myeloid blast crisis patients or of de novo Philadelphia chromosome-positive acute myeloid leukemia remains poor. We conducted a retrospective study on patients with advanced phase disease treated with a TKI and azacytidine. Sixteen patients were eligible. Median age was 64.9 years, the median number of previous therapies was 2.5 lines, and median follow-up was 23.1 months. Hematologic response (HR) rate was 81.3%. Median overall survival (OS), event free survival and relapse-free survival (RFS) were 31.5, 23.3, and 32.2 months, respectively. All except one patient were treated as out-patients after the first cycle. Five patients were bridged to allogenic hematopoietic stem cells transplant. The combination of a TKI and azacytidine is a safe and efficient regiment for patients with CML patients in advanced phases.

引用

页码：1659 / 1665

页数：7

共 31 条

[1] An Open-Label, Phase I Study of Dasatinib in Combination with Decitabine in Patients (Pts) with Accelerated or Blastic Phase Chronic Myeloid Leukemia (CML)
Abaza, Yasmin
Kantarjian, Hagop M.
Borthakur, Gautam
Daver, Naval
Ravandi, Farhad
Chihara, Dai
Verstovsek, Srdan
Burger, Jan A.
Estrov, Zeev
Ohanian, Maro
Jabbour, Elias
Cortes, Jorge E.
[J]. BLOOD, 2015, 126 (23)
[2] Intensive chemotherapy in patients with chronic myelogenous leukaemia (CML) in accelerated or blastic phase -: a report from the Swedish CML Group
Axdorph, U
Stenke, L
Grimfors, G
Carneskog, J
Hansen, J
Linder, O
Ljungman, P
Löfvenberg, E
Malm, C
Simonsson, B
Turesson, I
Vilén, L
Udén, AM
Björkholm, M
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2002, 118 (04) : 1048 - 1054
[3] European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Baccarani, Michele
Deininger, Michael W.
Rosti, Gianantonio
Hochhaus, Andreas
Soverini, Simona
Apperley, Jane F.
Cervantes, Francisco
Clark, Richard E.
Cortes, Jorge E.
Guilhot, Francois
Hjorth-Hansen, Henrik
Hughes, Timothy P.
Kantarjian, Hagop M.
Kim, Dong-Wook
Larson, Richard A.
Lipton, Jeffrey H.
Mahon, Francois-Xavier
Martinelli, Giovanni
Mayer, Jiri
Mueller, Martin C.
Niederwieser, Dietger
Pane, Fabrizio
Radich, Jerald P.
Rousselot, Philippe
Saglio, Giuseppe
Saussele, Susanne
Schiffer, Charles
Silver, Richard
Simonsson, Bengt
Steegmann, Juan-Luis
Goldman, John M.
Hehlmann, Ruediger
[J]. BLOOD, 2013, 122 (06) : 872 - 884
[4] The role of stem cell transplantation for chronic myelogenous leukemia in the 21st century
Barrett, A. John
Ito, Sawa
[J]. BLOOD, 2015, 125 (21) : 3230 - 3235
[5] Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population
Bower, Hannah
Bjorkholm, Magnus
Dickman, Paul W.
Hoglund, Martin
Lambert, Paul C.
Andersson, Therese M. -L.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (24) : 2851 - +
[6] Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase
Cortes, J.
Kim, D-W
Raffoux, E.
Martinelli, G.
Ritchie, E.
Roy, L.
Coutre, S.
Corm, S.
Hamerschlak, N.
Tang, J-L
Hochhaus, A.
Khoury, H. J.
Bruemmendorf, T. H.
Michallet, M.
Rege-Cambrin, G.
Gambacorti-Passerini, C.
Radich, J. P.
Ernst, T.
Zhu, C.
Van Tornout, J. M. A.
Talpaz, M.
[J]. LEUKEMIA, 2008, 22 (12) : 2176 - 2183
[7] The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study)
Deau, Benedicte
Nicolini, Franck E.
Guilhot, Joelle
Huguet, Francoise
Guerci, Agnes
Legros, Laurence
Pautas, Cecile
Berthou, Christian
Guyotat, Denis
Cony-Makhoul, Pascale
Gardembas, Martine
Michallet, Mauricette
Hayette, Sandrine
Cayuela, Jean Michel
Weiss, Isabelle Radford
Rea, Delphine
Castaigne, Sylvie
Mahon, Francois-Xavier
Guilhot, Francois
Rousselot, Philippe
[J]. LEUKEMIA RESEARCH, 2011, 35 (06) : 777 - 782
[8] Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis
Fruehauf, Stefan
Topaly, Julian
Buss, Eike C.
Fischer, Thomas
Offmann, Oliver G.
Emmerich, Bertold
Muller, Martin C.
Schuld, Peter
Balleisen, Leopold
Hehlmann, Rbdiger
Ho, Anthony D.
Hochhaus, Andreas
[J]. CANCER, 2007, 109 (08) : 1543 - 1549
[9] Clinical efficacy of second generation tyrosine kinase inhibitor and 5-azacytidine combination in chronic myelogenous leukaemia in myeloid blast crisis
Ghez, David
Micol, Jean-Baptiste
Pasquier, Florence
Auger, Nathalie
Saada, Veronique
Spentchian, Marc
Ianotto, Jean-Christophe
Bourhis, Jean-Henri
Bennaceur-Griscelli, Anelyse
Terre, Christine
Castaigne, Sylvie
Rigaudeau, Sophie
Rousselot, Philippe
de Botton, Stephane
[J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 (17) : 3666 - 3670
[10] Next-generation sequencing identifies major DNA methylation changes during progression of Ph plus chronic myeloid leukemia
Heller, G.
Topakian, T.
Altenberger, C.
Cerny-Reiterer, S.
Herndlhofer, S.
Ziegler, B.
Datlinger, P.
Byrgazov, K.
Bock, C.
Mannhalter, C.
Hoermann, G.
Sperr, W. R.
Lion, T.
Zielinski, C. C.
Valent, P.
Zoechbauer-Mueller, S.
[J]. LEUKEMIA, 2016, 30 (09) : 1861 - 1868

← 1 2 3 4 →